REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 18 filers reported holding REXAHN PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $2,663,000 | +721.9% | 5,222,073 | +128.4% | 0.00% | – |
| Q4 2016 | $324,000 | -68.7% | 2,286,623 | -53.6% | 0.00% | – |
| Q3 2016 | $1,035,000 | -16.0% | 4,927,397 | +0.5% | 0.00% | – |
| Q2 2016 | $1,232,000 | -23.1% | 4,904,097 | +1.0% | 0.00% | – |
| Q1 2016 | $1,602,000 | -9.9% | 4,854,336 | -0.9% | 0.00% | – |
| Q4 2015 | $1,778,000 | -29.6% | 4,898,122 | +0.8% | 0.00% | – |
| Q3 2015 | $2,527,000 | -13.7% | 4,860,087 | +0.8% | 0.00% | – |
| Q2 2015 | $2,929,000 | -13.7% | 4,819,441 | +3.7% | 0.00% | – |
| Q1 2015 | $3,394,000 | +11.8% | 4,649,423 | +7.2% | 0.00% | – |
| Q4 2014 | $3,037,000 | -8.7% | 4,338,622 | +5.7% | 0.00% | – |
| Q3 2014 | $3,325,000 | +6.9% | 4,105,784 | +14.9% | 0.00% | – |
| Q2 2014 | $3,109,000 | -19.0% | 3,574,300 | +0.6% | 0.00% | – |
| Q1 2014 | $3,839,000 | +280.5% | 3,554,400 | +79.6% | 0.00% | – |
| Q4 2013 | $1,009,000 | +13.4% | 1,978,577 | 0.0% | 0.00% | – |
| Q3 2013 | $890,000 | +156.5% | 1,978,577 | +153.2% | 0.00% | – |
| Q2 2013 | $347,000 | – | 781,357 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Northeast Financial Consultants Inc | 150,000 | $105,000 | 0.06% |
| Benin Management CORP | 83,000 | $58,000 | 0.03% |
| CONDOR CAPITAL MANAGEMENT | 121,324 | $85,000 | 0.02% |
| First Heartland Consultants, Inc. | 30,000 | $21,000 | 0.01% |
| FCG ADVISORS, LLC | 15,000 | $11,000 | 0.01% |
| Advisory Services Network, LLC | 22,000 | $16,000 | 0.01% |
| Virtu KCG Holdings LLC | 346,822 | $243,000 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 180,000 | $126,000 | 0.00% |
| Moors & Cabot, Inc. | 18,000 | $12,000 | 0.00% |
| Corbenic Partners LLC | 1,600 | $1,000 | 0.00% |